Alpha Cognition ZUNVEYL™ Q1 2025 Launch Strategy

Description

Join Alpha Cognition as they present their commercial launch strategy for ZUNVEYL (benzgalantamine), an FDA-approved treatment for mild-to-moderate Alzheimer’s disease (AD). The call will focus on the company’s plans to address the needs of a growing patient population within the $2 billion long-term care market in the U.S.